In recent years, targeted drugs such as the FGFR3 inhibitor erdafitinib and immunotherapies such as the PD-1/PD-L1 inhibitors nivolumab and atezolizumab have been approved for the treatment of BC, bringing new hope to BC patients 3, 4. The gene discussed is FGFR3; the disease is breast cancer.